



25. Jennings T, Li Y, Pinto H, et al. Phase II trial of paclitaxel in advanced or metastatic salivary gland malignancies: an Eastern Cooperative Oncology Group Study. *Proc Am Soc Clin Oncol*. 2001;20:236a.
26. Pignon J, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell cancer: three meta-analysis of updated individual data. *Lancet*. 2000;355:949–955.
27. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *New Engl J Med*. 2004;350:1945–1952.
28. Tishler R, Schiff P, Geard C, et al. Taxol: a novel radiation sensitizer. *Int J Radiat Oncol Biol Physics*. 1992;22:613–617.
29. Tishler R, Geard C, Hall E, et al. Taxol sensitizes human astrocytoma cells to radiation. *Cancer Res*. 1992;52:3495–3497.
30. Milas L, Hunter N, Mason K, et al. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. *Cancer Res*. 1994;54:3506–2510.
31. Milas L, Saito Y, Hunter N, et al. Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma. *Radiother Oncol*. 1996;40:163–167.
32. Haddad A, Enepekides DJ, Manolidis S, et al. Adenoid cystic carcinoma of the head and neck: a clinicopathologic study of 37 cases. *J Otolaryngol*. 1995;24:201–205.